Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;40(3):481-5.
doi: 10.1007/s12020-011-9501-2. Epub 2011 Jun 17.

Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian family

Affiliations

Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian family

Sandra Mastroianno et al. Endocrine. 2011 Dec.

Abstract

To describe the coexistence of mutations of both the multiple endocrine neoplasia type 1 (MEN1) and type 2 (MEN2) genes in a large Italian family and evaluate if it could be associated with more aggressive clinical manifestations of the two syndromes. Blood samples were obtained for genetic and biochemical analyses. The RET gene exons (8, 10, 11, 13, 14, 15, 16, 18) and the MEN1 coding regions, including the exon-intron boundaries, were amplified by PCR and directly sequenced. We identified two germline mutations in the proband: the first one, K666M, located at the exon 11 of RET proto-oncogene and the second one, IVS4+1G>T, located in the MEN1 gene. The functional characterization of IVS4+1G>T variation, located in the splicing donor site of exon 4 of MEN1 gene, caused the in-frame junction of exon 3 to exon 5, thus obtaining a shorter protein. The same proband's germline mutations were found in 16 relatives out of 21 screened subjects: 8 carried IVS4+1G>T, 4 RET K666M, and 4 both the mutations. This is the second report in literature of coexistence in the same family of germline mutations of both RET proto-oncogene and MEN1 gene. The simultaneous presence of the two mutations was not apparently associated with more aggressive diseases, since at last follow-up all patients appeared to be disease-free or well compensated by medical therapy; finally, no one exhibited metastatic diseases.

PubMed Disclaimer

References

    1. Mod Pathol. 1999 Sep;12(9):919-24 - PubMed
    1. Semin Surg Oncol. 2000 Jun;18(4):324-32 - PubMed
    1. J Clin Endocrinol Metab. 2005 Jul;90(7):4063-7 - PubMed
    1. JAMA. 2006 May 10;295(18):2164-7 - PubMed
    1. Hum Mutat. 2008 Jan;29(1):22-32 - PubMed

Publication types

MeSH terms

LinkOut - more resources